Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function

被引:13
作者
Devay, Rachel M. [1 ]
Yamamoto, Lynn [1 ]
Shelton, David L. [1 ]
Liang, Hong [1 ]
机构
[1] Rinat Pfizer Inc, San Francisco, CA 94080 USA
关键词
DENSITY-LIPOPROTEIN RECEPTORS; SECRETED PCSK9; LDL RECEPTORS; ANTIBODY; CHOLESTEROL; DOMAIN; TRAFFICKING; DEGRADATION; PLASMA; BINDS;
D O I
10.1371/journal.pone.0125127
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble protein that directs membrane-bound receptors to lysosomes for degradation. In the most studied example of this, PCSK9 binding leads to the degradation of low density lipoprotein receptor (LDLR), significantly affecting circulating LDL-C levels. The mechanism mediating this degradation, however, is not completely understood. We show here that LDLR facilitates PCSK9 interactions with amyloid precursor like protein 2 (APLP2) at neutral pH leading to PCSK9 internalization, although direct binding between PCSK9 and LDLR is not required. Moreover, binding to APLP2 or LDLR is independently sufficient for PCSK9 endocytosis in hepatocytes, while LDL can compete with APLP2 for PCSK9 binding to indirectly mediate PCSK9 endocytosis. Finally, we show that APLP2 and LDLR are also required for the degradation of another PCSK9 target, APOER2, necessitating a general role for LDLR and APLP2 in PCSK9 function. Together, these findings provide evidence that PCSK9 has at least two endocytic epitopes that are utilized by a variety of internalization mechanisms and clarifies how PCSK9 may direct proteins to lysosomes.
引用
收藏
页数:20
相关论文
共 33 条
[1]
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].
Abifadel, M ;
Varret, M ;
Rabès, JP ;
Allard, D ;
Ouguerram, K ;
Devillers, M ;
Cruaud, C ;
Benjannet, S ;
Wickham, L ;
Erlich, D ;
Derré, A ;
Villéger, L ;
Farnier, M ;
Beucler, I ;
Bruckert, E ;
Chambaz, J ;
Chanu, B ;
Lecerf, JM ;
Luc, G ;
Moulin, P ;
Weissenbach, J ;
Prat, A ;
Krempf, M ;
Junien, C ;
Seidah, NG ;
Boileau, C .
NATURE GENETICS, 2003, 34 (02) :154-156
[2]
Canuel M, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0064145, DOI 10.1371/J0URNAL.P0NE.0064145]
[3]
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates [J].
Chan, Joyce C. Y. ;
Piper, Derek E. ;
Cao, Qiong ;
Liu, Dongming ;
King, Chadwick ;
Wang, Wei ;
Tang, Jie ;
Liu, Qiang ;
Higbee, Jared ;
Xia, Zhen ;
Di, Yongmei ;
Shetterly, Susan ;
Arimura, Ziva ;
Salomonis, Heather ;
Romanow, William G. ;
Thibault, Stephen T. ;
Zhang, Richard ;
Cao, Ping ;
Yang, Xiao-Ping ;
Yu, Timothy ;
Lu, Mei ;
Retter, Marc W. ;
Kwon, Gayle ;
Henne, Kirk ;
Pan, Oscar ;
Tsai, Mei-Mei ;
Fuchslocher, Bryna ;
Yang, Evelyn ;
Zhou, Lei ;
Lee, Ki Jeong ;
Daris, Mark ;
Sheng, Jackie ;
Wang, Yan ;
Shen, Wenyan D. ;
Yeh, Wen-Chen ;
Emery, Maurice ;
Walker, Nigel P. C. ;
Shan, Bei ;
Schwarz, Margrit ;
Jackson, Simon M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (24) :9820-9825
[4]
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9 [J].
Chaparro-Riggers, Javier ;
Liang, Hong ;
DeVay, Rachel M. ;
Bai, Lanfang ;
Sutton, Janette E. ;
Chen, Wei ;
Geng, Tao ;
Lindquist, Kevin ;
Casas, Meritxell Galindo ;
Boustany, Leila M. ;
Brown, Colleen L. ;
Chabot, Jeffrey ;
Gomes, Bruce ;
Garzone, Pamela ;
Rossi, Andrea ;
Strop, Pavel ;
Shelton, Dave ;
Pons, Jaume ;
Rajpal, Arvind .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (14) :11090-11097
[5]
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease [J].
Cohen, JC ;
Boerwinkle, E ;
Mosley, TH ;
Hobbs, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1264-1272
[6]
Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2) [J].
DeVay, Rachel M. ;
Shelton, David L. ;
Liang, Hong .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (15) :10805-10818
[7]
Self-association of human PCSK9 correlates with its LDLR-degrading activity [J].
Fan, Daping ;
Yancey, Patricia G. ;
Qiu, Shenfeng ;
Ding, Lei ;
Weeber, Edwin J. ;
Linton, MacRae F. ;
Fazio, Sergio .
BIOCHEMISTRY, 2008, 47 (06) :1631-1639
[8]
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation [J].
Fisher, Timothy S. ;
Lo Surdo, Paola ;
Pandit, Shilpa ;
Mattu, Marco ;
Santoro, Joseph C. ;
Wisniewski, Doug ;
Cummings, Richard T. ;
Calzetta, Alessandra ;
Cubbon, Rose M. ;
Fischer, Paul A. ;
Tarachandani, Anil ;
De Francesco, Raffaele ;
Wright, Samuel D. ;
Sparrow, Carl P. ;
Carfi, Andrea ;
Sitlani, Ayesha .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (28) :20502-20512
[9]
Plasma PCSK9 preferentially reduces liver LDL receptors in mice [J].
Grefhorst, Aldo ;
McNutt, Markey C. ;
Lagace, Thomas A. ;
Horton, Jay D. .
JOURNAL OF LIPID RESEARCH, 2008, 49 (06) :1303-1311
[10]
Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors [J].
Holla, Oystein L. ;
Cameron, Jamie ;
Tveten, Kristian ;
Strom, Thea Bismo ;
Berge, Knut Erik ;
Laerdahl, Jon K. ;
Leren, Trond P. .
JOURNAL OF LIPID RESEARCH, 2011, 52 (10) :1787-1794